A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2026

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

Bivalent RSV Vaccine (IN006)

Formulation for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

All Listed Sponsors

lead

Shenzhen Shenxin Biotechnology Co., Ltd

INDUSTRY